Clinical Trial: The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.

U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07069725) titled 'The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.' on May 09.

Brief Summary: This is a phase 1, open-label, PET trial. The study is designed to investigate the effect of AZD2389 on FAP occupancy in the liver in participants with advanced liver fibrosis.

Study Start Date: May 26

Study Type: INTERVENTIONAL

Condition: Liver Fibrosis Hepatic Cirrhosis

Intervention: DRUG: AZD2389

Doses of AZD2389 will be administrated orally

DIAGNOSTIC_TEST: PET scan and radioligand

PET scan and radioligand

Recruitment Status: RECRUITING ...